|Bid||33.05 x 1100|
|Ask||36.25 x 1100|
|Day's range||33.44 - 35.04|
|52-week range||28.53 - 73.47|
|Beta (5Y monthly)||1.58|
|PE ratio (TTM)||4.02|
|Earnings date||21 Feb 2023 - 27 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||45.00|
TEMPLE CITY, Calif., January 03, 2023--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent Genetics", "Fulgent" or the "company") today announced the addition of Reggie Groves to its board of directors, effective January 3, 2023.
If you want to know who really controls Fulgent Genetics, Inc. ( NASDAQ:FLGT ), then you'll have to look at the makeup...
Fulgent Genetics (NASDAQ: FLGT) has been a fascinating company to watch over the past few years. While that's an impressive market beat, there was a point in early 2021 when Fulgent's stock was up over 1,300%. This wild stock movement was spurred on by incredible revenue growth due to Fulgent's ability to pivot to providing COVID-19 tests early in 2020.